AI Tokens
Stock Analysis on Net

Shockwave Medical Inc. (NASDAQ:SWAV)

This company has been moved to the archive! The financial data has not been updated since May 6, 2024.

Return on Capital (ROC)

Microsoft Excel

Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.


Return on Invested Capital (ROIC)

Shockwave Medical Inc., ROIC calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1 170,498 122,053 (7,113) (64,111) (49,755)
Invested capital2 672,462 318,057 174,255 91,274 158,673
Performance Ratio
ROIC3 25.35% 38.37% -4.08% -70.24% -31.36%
Benchmarks
ROIC, Competitors4
Abbott Laboratories 8.87% 10.96% 11.30% — —
Elevance Health Inc. 9.21% 10.24% 11.26% — —
Intuitive Surgical Inc. 22.30% 22.01% 37.63% — —
Medtronic PLC 5.89% 7.02% 5.59% — —
UnitedHealth Group Inc. 14.59% 13.68% 13.51% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 NOPAT. See details »

2 Invested capital. See details »

3 2023 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 170,498 ÷ 672,462 = 25.35%

4 Click competitor name to see calculations.


Between 2019 and 2023, a transition from substantial operational losses to significant profitability was observed. The financial trajectory indicates a period of initial instability followed by a rapid scale-up in operational efficiency and a massive expansion of the capital base.

Net Operating Profit After Taxes (NOPAT)
Operational performance showed a strong upward trend. After reaching a low of negative $64.1 million in 2020, NOPAT improved significantly, nearing a break-even point in 2021 before turning positive. By December 31, 2023, NOPAT reached $170.5 million, reflecting a successful transition to a profit-generating operational model.
Invested Capital
The capital base experienced substantial growth, particularly from 2021 onward. After a contraction in 2020 to $91.3 million, invested capital rose steadily, peaking at $672.5 million in 2023. The sharp increase between 2022 and 2023, where capital more than doubled, suggests aggressive investment in growth or asset acquisition.
Return on Invested Capital (ROIC)
ROIC exhibited significant volatility before normalizing in positive territory. A sharp decline to -70.24% in 2020 was followed by a rapid recovery, peaking at 38.37% in 2022. While the 2023 ROIC of 25.35% remains strong, the decrease from the previous year indicates that the expansion of the invested capital base outpaced the growth in NOPAT, leading to a moderation in capital efficiency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Decomposition of ROIC

Shockwave Medical Inc., decomposition of ROIC

Microsoft Excel
ROIC = OPM1 × TO2 × 1 – CTR3
Dec 31, 2023 25.35% = 25.29% × 1.09 × 92.33%
Dec 31, 2022 38.37% = 25.51% × 1.54 × 97.68%
Dec 31, 2021 -4.08% = -2.64% × 1.36 × 100.00%
Dec 31, 2020 -70.24% = -93.91% × 0.74 × 100.00%
Dec 31, 2019 -31.36% = -115.00% × 0.27 × 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Operating profit margin (OPM). See calculations »

2 Turnover of capital (TO). See calculations »

3 Effective cash tax rate (CTR). See calculations »


The financial performance between 2019 and 2023 is characterized by a transition from significant operational losses to sustainable profitability. This turnaround is evidenced by the trajectory of the Return on Invested Capital (ROIC), which evolved from deep negative values to a peak of 38.37% in 2022, before settling at 25.35% in 2023.

Operating Profit Margin (OPM)
A substantial recovery in operational efficiency is observed. The margin improved from -115.00% in 2019 to a positive 25.51% in 2022, remaining relatively stable at 25.29% in 2023. This trend indicates a successful shift from an early-stage investment phase to a scalable, profitable operational model.
Turnover of Capital (TO)
Capital efficiency exhibited a strong upward trend in the first four years, rising from a ratio of 0.27 in 2019 to a peak of 1.54 in 2022. This suggests an increasing capacity to generate revenue relative to the invested capital. However, a decline to 1.09 occurred in 2023, indicating a reduction in asset productivity or an increase in the capital base that has not yet been matched by proportional revenue growth.
Effective Cash Tax Rate (CTR) Impact
The tax component remained neutral at 100% from 2019 through 2021, confirming that no cash taxes were paid during the period of operational losses. Following the shift to profitability, the value decreased to 97.68% in 2022 and 92.33% in 2023, reflecting the introduction of cash tax obligations that slightly compress the final ROIC.
ROIC Decomposition and Synthesis
The fluctuations in ROIC are the result of the interplay between profit margins and capital turnover. The sharp decline in 2020 was driven by the combination of high operational losses and expanding capital requirements. The subsequent surge in 2022 was powered by the simultaneous achievement of positive operating margins and peak capital turnover. The moderate decline in 2023 is attributed primarily to the reduction in capital turnover, as the operating profit margin remained consistent.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Operating Profit Margin (OPM)

Shockwave Medical Inc., OPM calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1 170,498 122,053 (7,113) (64,111) (49,755)
Add: Cash operating taxes2 14,167 2,898 847 453 390
Net operating profit before taxes (NOPBT) 184,665 124,951 (6,266) (63,658) (49,365)
 
Revenue 730,230 489,733 237,146 67,789 42,927
Profitability Ratio
OPM3 25.29% 25.51% -2.64% -93.91% -115.00%
Benchmarks
OPM, Competitors4
Abbott Laboratories 16.84% 20.24% 20.37% — —
Elevance Health Inc. 5.32% 5.64% 6.58% — —
Intuitive Surgical Inc. 28.14% 26.19% 33.56% — —
Medtronic PLC 19.63% 19.15% 16.48% — —
UnitedHealth Group Inc. 9.14% 9.13% 8.33% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2023 Calculation
OPM = 100 × NOPBT ÷ Revenue
= 100 × 184,665 ÷ 730,230 = 25.29%

4 Click competitor name to see calculations.


An analysis of the financial performance from 2019 to 2023 reveals a significant transition from an early-stage loss-making position to established operational profitability. The company experienced exponential revenue growth coupled with a rapid improvement in operating efficiency, culminating in a stabilized profit margin by the end of the period.

Revenue Trajectory
Revenue grew consistently and aggressively, increasing from US$ 42,927 thousand in 2019 to US$ 730,230 thousand in 2023. This substantial growth indicates a successful scaling of operations and market penetration over the five-year window.
Net Operating Profit Before Taxes (NOPBT) Evolution
The NOPBT shifted from a deficit of US$ 49,365 thousand in 2019 to a positive US$ 184,665 thousand by 2023. Although operating losses widened slightly in 2020, a critical inflection point occurred in 2021, where losses were nearly eliminated, followed by a shift to positive territory in 2022.
Operating Profit Margin (OPM) Analysis
The OPM demonstrated a dramatic recovery, ascending from -115.00% in 2019 to 25.29% in 2023. The margin improved sharply between 2020 and 2022, moving from -93.91% to 25.51%. The marginal difference between the 2022 and 2023 OPM suggests that the company has achieved a state of operational maturity and stable cost management relative to its revenue stream.

The overall trend indicates that the company successfully leveraged its revenue growth to offset fixed operating costs, resulting in a sustainable operating profit margin of approximately 25%.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Turnover of Capital (TO)

Shockwave Medical Inc., TO calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Revenue 730,230 489,733 237,146 67,789 42,927
Invested capital1 672,462 318,057 174,255 91,274 158,673
Efficiency Ratio
TO2 1.09 1.54 1.36 0.74 0.27
Benchmarks
TO, Competitors3
Abbott Laboratories 0.67 0.71 0.69 — —
Elevance Health Inc. 2.44 2.33 2.14 — —
Intuitive Surgical Inc. 1.00 1.16 1.27 — —
Medtronic PLC 0.44 0.46 0.42 — —
UnitedHealth Group Inc. 2.01 1.95 2.04 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Invested capital. See details »

2 2023 Calculation
TO = Revenue ÷ Invested capital
= 730,230 ÷ 672,462 = 1.09

3 Click competitor name to see calculations.


The financial trajectory from 2019 to 2023 is characterized by aggressive revenue expansion and a corresponding increase in the capital base, leading to significant fluctuations in capital efficiency.

Revenue Growth Trends
A consistent and rapid upward trend in revenue is observed, scaling from US$ 42.9 million in 2019 to US$ 730.2 million by 2023. The most pronounced acceleration occurred between 2020 and 2022, where annual revenues increased more than sevenfold.
Invested Capital Dynamics
Invested capital exhibited a non-linear progression. After an initial decrease from US$ 158.7 million in 2019 to US$ 91.3 million in 2020, there was a sustained and sharp increase. By December 31, 2023, invested capital reached US$ 672.5 million, indicating a substantial reallocation of resources to support the expanding scale of operations.
Turnover of Capital (TO) Analysis
The turnover of capital ratio demonstrated a strong positive trend during the first four years, rising from 0.27 in 2019 to a peak of 1.54 in 2022. This indicates a period of increasing operational efficiency where revenue growth significantly outpaced the growth of the invested capital base.
Recent Efficiency Shift
A decline in the turnover ratio is noted in 2023, dropping to 1.09. While revenue continued to grow, the rate of increase in invested capital—which more than doubled from US$ 318.1 million to US$ 672.5 million—exceeded the rate of revenue growth. This suggests a recent phase of heavy capital investment that has yet to be fully reflected in proportional revenue gains.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Effective Cash Tax Rate (CTR)

Shockwave Medical Inc., CTR calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1 170,498 122,053 (7,113) (64,111) (49,755)
Add: Cash operating taxes2 14,167 2,898 847 453 390
Net operating profit before taxes (NOPBT) 184,665 124,951 (6,266) (63,658) (49,365)
Tax Rate
CTR3 7.67% 2.32% — — —
Benchmarks
CTR, Competitors4
Abbott Laboratories 21.67% 23.97% 20.05% — —
Elevance Health Inc. 29.13% 22.01% 20.22% — —
Intuitive Surgical Inc. 20.94% 27.40% 11.76% — —
Medtronic PLC 32.28% 19.53% 18.59% — —
UnitedHealth Group Inc. 20.64% 23.25% 20.32% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2023 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 14,167 ÷ 184,665 = 7.67%

4 Click competitor name to see calculations.


The financial trajectory indicates a significant transition from operational losses to substantial profitability over the five-year period. Net operating profit before taxes (NOPBT) remained negative from 2019 through 2021, reaching a low of -63.6 million USD in 2020, before pivoting to a positive 124.9 million USD in 2022 and further expanding to 184.6 million USD by 2023.

Net Operating Profit Before Taxes (NOPBT)
A strong recovery trend is observed, with NOPBT shifting from a deficit of 49.3 million USD in 2019 to a surplus of 184.6 million USD in 2023. This indicates a successful transition toward operational sustainability and growth.
Cash Operating Taxes
Cash tax payments exhibited consistent growth throughout the period. While payments were minimal during the loss-making years, there was a sharp escalation between 2022 and 2023, where payments increased from 2.8 million USD to 14.1 million USD, reflecting the increased tax burden associated with rising profitability.
Effective Cash Tax Rate (CTR)
The effective cash tax rate became calculable following the achievement of positive NOPBT in 2022. The CTR rose from 2.32% in 2022 to 7.67% in 2023. This upward trend suggests that a larger portion of operating profit is being subjected to cash tax payments, although the overall rate remains relatively low, potentially due to the utilization of tax credits or the amortization of previous losses.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?